Fig. 8From: Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancerAssociation of the risk model with chemotherapy and analysis of potential drugs. A Evaluation of IC50 for four common chemotherapeutic medicines. B Expression levels of PD-L1, CTLA4, HAVCR2, PD-1 in the high- and low-risk groups. C Differential analysis of potential drug sensitivityBack to article page